.png){kind=icon}
返回
Iterative Causal Forest: A Novel Algorithm for Subgroup Identification
.png){kind=icon}
OA
AI
DOI：10.1093/aje/kwad219.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Precisely and efficiently identifying subgroups with heterogeneous treatment effects (HTEs) in real-world evidence studies remains a challenge. Based on the causal forest (CF) method, we developed an iterative CF (iCF) algorithm to identify HTEs in subgroups defined by important variables. Our method iteratively grows different depths of the CF with important effect modifiers, performs plurality votes to obtain decision trees (subgroup decisions) for a family of CFs with different depths, and then finds the cross-validated subgroup decision that best predicts the treatment effect as a final subgroup decision. We simulated 12 different scenarios and showed that the iCF outperformed other machine learning methods for interaction/subgroup identification in the majority of scenarios assessed. Using a 20% random sample of fee-for-service Medicare beneficiaries initiating sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists, we implemented the iCF to identify subgroups with HTEs for hospitalized heart failure. Consistent with previous studies suggesting patients with heart failure benefit more from sodium-glucose cotransporter-2 inhibitors, iCF successfully identified such a subpopulation with HTEs and additive interactions. The iCF is a promising method for identifying subgroups with HTEs in real-world data where the potential for unmeasured confounding can be limited by study design.
Keyword:
causal forest
heterogeneous treatment effect
iterative causal forest
pharmacoepidemiology
precision medicine
subgroup identification
期刊
IF:
4.8
论文数:
10.0K
被引数:
3.7W
机构
引用论文
分享收藏Management of Vitreous Cavity Hemorrhage Following Pars Plana Vitrectomy for Diabetic Retinopathy
OAAI
OAAI分享收藏Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial杜拉鲁肽与2型糖尿病的心血管结局 (REWIND): 一项双盲，随机安慰剂对照试验.png)
LANCET
LANCETIF88.5
PREAI
分享收藏Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesCanagliflozin与2型糖尿病的心血管和肾脏事件OAAI
OAAI分享收藏Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesSemaglutide与2型糖尿病患者的心血管结局OAAI
OAAI分享收藏
查看更多内容